Keyword: Stivarga

Markets & Companies

The Future Lies in the Genome

07.10.2015 - Kemal Malik, board member for innovation at the German Bayer Group, sees many similarities in the genetic system of humans, animals and plants. This opens the door for synergies in...

News

Bayer Has “Great Plans” for Life Sciences, CEO Says

12.03.2015 - Bayer aims to achieve strong sales and earnings growth for its life science businesses in the coming years, CEO Marijn Dekkers said at the "Meet Management" investor conference in...

News

Avella to Distribute Bayer’s Nexavar and Stivarga in US

23.02.2015 - Bayer has named Avella Specialty Pharmacy as one of the limited group of specialty pharmacies authorized to distribute two of its oral oncology drugs, Nexavar (sorafenib) and...

News

Bayer Buoyed by Health and Agriculture in Q3

31.10.2014 - Buoyed by a strong performance in its Healthcare and CropScience businesses in the third quarter, Bayer has raised its forecast for full year 2014. CEO Marijn Dekkers said he...

News

Bayer Expects to Meet Earnings Forecast Despite Polymer Woes

05.11.2013 - With three quarters of 2013 behind it, Germany's Bayer group sees itself as still on track to fulfil the "ambitious forecast" for 2013 voiced by CEO Marijn Dekkers earlier this...

News

Amgen Buys Onyx for $10.4 Billion

26.08.2013 - Amgen struck a deal to buy cancer drug maker Onyx Pharmaceuticals for about $10.4 billion on Sunday, as it moves to restock its product pipeline in response to declining sales of...

News

Amgen deal for Onyx possible Within Week

09.08.2013 - Onyx Pharmaceuticals is close to selling itself to larger rival Amgen as the cancer drug maker's high stock price has discouraged other companies from making a counteroffer so far...

News

Pfizer, Novartis May Join Amgen in Bidding for Onyx

02.07.2013 - Onyx Pharmaceuticals, whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer and...